Bid moving up nicely |
10.7m volume - it's not even 9am yet |
Quite simply buy and hold and no one can hold it down - patience always pays with good stocks. |
I think you have to set a sell order the night before if you want to sell for more on the markup during the auction. Otherwise there is no option for getting the highest price. I can remember when they offered 7p to sell and I ended up getting 3p earlier in the year. |
Highest sell price was 1.7p all morning. No good for traders in and out. |
Media coverage over the weekend will be crazy - new buyers will take over. |
Concur but can see at least 10p+ in the relatively short term |
Quite simply buy a stash and hold-this was 7p not too long ago. |
Basically HEMO are currently in share price terms at the foot hills of the Himilayars getting prepared for the very steep climb up to the very highest summit! |
And to all the very many de-rampers, shorters and TROLLs out there....this is just the start for HEMO |
Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented:
"We are excited to receive IRB approval to proceed with our Phase I clinical trial of HEMO-CAR-T. This trial is a critical step in the development of our CAR-T therapy for AML patients who have exhausted other treatment options. With this study, we aim to establish the safety profile of HG-CT-1 and gather preliminary efficacy data that could pave the way for future therapeutic development." |
3p+ next week |
Well done Hemo! |
The negative trolls at 1.1p deserve shooting for this. |
I never ramped so hard as I have done here in my life and that was because I was so confident. |
There is still a long way to go before PROOF & Profit. |
Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented:
"We are excited to receive IRB approval to proceed with our Phase I clinical trial of HEMO-CAR-T. This trial is a critical step in the development of our CAR-T therapy for AML patients who have exhausted other treatment options. With this study, we aim to establish the safety profile of HG-CT-1 and gather preliminary efficacy data that could pave the way for future therapeutic development." |
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE:HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.
The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases.
Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development. |
positive news |
At least with spread betting you can transfer or withdraw the available funds if a bad rns happens before or after close. I can see myself wanting to ride this one all the way for it to become my first 100 bagger. |
And it ain't going to take much to double this.Went to 7 on FDA reinstatement |
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Hot Features
Premium
